CURIS INC (CRIS): M&A transaction — Curis sells Erivedge royalty rights to Oberland for $2.5M; Q3 net loss narrows to $7.7M

CURIS INC

Sold Erivedge IP and license rights to Oberland affiliate for $2.5M upfront and release of future royalty liability.
Q3 2025 net loss $7.7M ($0.49/sh), improved from $10.1M loss in Q3 2024.
Revenue from Erivedge royalties $3.2M in Q3; company will recognize gain but no future Erivedge revenues.
Cash $9.1M as of Sep 30; expects to fund operations into early 2026.
Nasdaq granted extension to Nov 14 to regain MVLS compliance; company believes equity now exceeds $2.5M threshold.

item 1.02 item 2.01 item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

CURIS INC completed a disposition involving Royalty Pharma plc for $125,000,000 (closed 2025-11-06).

Action: disposition
Counterparty: Royalty Pharma plc
Consideration: $125,000,000
Closing: 2025-11-06

Exact text from the filing

On November 6, 2025 (the “Closing Date”), the Company completed its sale of the Erivedge Business.

View on SEC.gov

Browse all m&a transactions →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-25-000105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.